Vioxx news from FiercePharma
NewsPfizer starts settling Celebrex claims
Pfizer is starting to settle the thousands of lawsuits over painkillers Celebrex and Bextra, the Wall Street Journal reports. Three groups of plaintiffs who allege that the meds caused heart attacks Read more...
Merck CEO: 'I can't blame the media'
A triad of Merck news today, including one item about the news. We'll start with that: CEO Dick Clark (photo) Read more...
Ghostwriting fuels foes of FDA rule change
Last week, we reported on Big Pharma's march on the capital in support of new off-label marketing rules. Read more...
Pharma fighting back in Washington
Call it the backlash against the backlash. In the wake of the recent Read more...
JAMA: Merck paid docs for bylines
Merck wrote its own articles on Vioxx research and then paid prestigious doctors to append their bylines, according to a new story in the Journal of the American Medical Association. Of course, Read more...
Forbes to Big Pharma: Fess up
Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin Read more...
Could full data disclosure avert scandal?
New calls for old drug data in the U.K. have experts second-guessing big drug-safety scandals. If scientists and regulators had had access to every bit of data on Vioxx from the get-go, for instance, Read more...
MPs lobby Merck for U.K. Vioxx deal
Now Parliament wants Merck to give U.K. patients a cut. MPs are hopping mad that the company is settling with U.S. Vioxx claimants to the tune of Read more...
Vioxx plaintiffs sign on, deal proceeds
The Vioxx deal is a go. Enough plaintiffs have signed on to the $4.85 billion settlement to move forward, Read more...
Canadian Vioxx plaintiffs get class status
Just as Merck lawyers magnanimously gave Vioxx plaintiffs more time to get their paperwork done so they might share in the $4.85 billion settlement, a class action lawsuit over the painkiller has Read more...
| Press ReleasesPRESS RELEASE: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits Merck Agreement to Resolve U.S. VIOXX® Product Liability Lawsuits Agreement Provides for $4.85 Billion Payment WHITEHOUSE STATION, N.J., Nov. 9, 2007 - Merck & Co., Inc. today announced Read more... PRESS RELEASE: Cuomo, Bloomberg Sue Maker of Vioxx for Hiding Drug's Risks Cuomo, Bloomberg Sue Maker of Vioxx for Hiding Drug's Risks FirstTime State and City Bring Joint Action to Fight Medicaid Fraud Suit claims Merck & Co. endangered patients, cost Medicaid Read more... PRESS RELEASE: New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking VIOXX Reimbursements New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking VIOXX® Reimbursements WHITEHOUSE STATION, N.J., Sept. 6, 2007 - Merck & Co., Inc. is pleased that Read more... |
Get more Vioxx coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight